Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

Cancer of Colon Clinical Trial

Official title:

Cetuximab Monotherapy or Cetuximab + Chemotherapy for Third Line Rechallenge in Metastatic Colorectal Cancer, RAS+ (RAt Sarcoma Gene) Wild Type Patients, Who Were Treated With Cetuximab Chemotherapy as First Line Treatment

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03524820
• Other study ID #: 0436-17
• Status: Terminated
• Phase: Phase 2
• Start date: October 17, 2017
• Est. completion date: December 31, 2021

Study information

• Verified date: February 2021
• Source: Hadassah Medical Organization
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research is intended to check the benefit of treatment with cetuximab in metastatic colorectal cancer patients with wild type RAS as third line treatment. The advantage to the patients is unclear. This study will look if mutations in patients' blood area predictive marker for progression free time (FPT) in metastatic colorectal cancer patients treated with third line cetuximab. A predictive marker for FPT metastatic colorectal cancer patients treated with third line cetuximab will enable a reduction in the number of treated patients. Treatment only of patients with a positive marker is expected to prevent inefficient treatment which will reduce suffering for the patients and reduce unnecessary medical treatment.

Description:

This research is intended to check the benefit of treatment with cetuximab in metastatic colorectal cancer patients with wild type RAS as third line treatment, following first line cetuximab treatment and other second line treatments. The hypothesis is that most cetuximab sensitive cells will be eliminated in the first line of treatment, but may reemerge following other second line treatments which are targeted to other clones in the tumor. The advantage to the patients is unclear, however some preliminary studies show advantage to patients. This study will look if mutations in patients' blood are a predictive marker for progression free time (FPT) in metastatic colorectal cancer patients treated with third line cetuximab. A predictive marker for FPT metastatic colorectal cancer patients treated with third line cetuximab will enable a reduction in the number of treated patients. Treatment only of patients with a positive marker is expected to prevent inefficient treatment which will reduce suffering for the patients and reduce unnecessary medical treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

Inclusion Criteria:

• Men and women over 18

• Tissue diagnosis of metastatic colon cancer without operational or radiation therapy options

• No RAS mutation in tumor tissue

• Measurable disease according to RACIST criteria v1.1

• ECOG ( Eastern Cooperative Oncology Group) performance status <=2

• Life expectancy of over 3 months

• Women of fertility age not pregnant

• Ability to understand and sign and informed consent form to participate in the trial and the ability to perform the treatment and follow up required for participation in the trial

• At least three months progression free time in first line cetuximab treatment

• Disease progression according to RACIST v1.1 for first and second lines

• Third line treatment will be applied no less then 17 weeks following and of first line treatment

Exclusion Criteria:

• RAS mutation carriers, or patients with uncertain metastatic colon cancer diagnosis

• Patients operated two weeks prior to accepting trail drug, or that did not recover from treatment

• Level 3 allergic response to any of trial drugs

• First line cetuximab treatment stopped due to allergic response

• Severe medical or mental diagnosis which might increase the risk in drug administration according to treating physician's discretion

• Pregnant or lactating women

Related Conditions & MeSH terms

• Cancer of Colon
• Colonic Neoplasms

Intervention

Drug:
• Cetuximab
Administration of drug

Locations

Country	Name	City	State
Israel	Hadassah Ein Kerem	Jerusalem

Sponsors (2)

Lead Sponsor	Collaborator
Hadassah Medical Organization	Merck Serono International SA

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	response to treatment	CT based on standard RECIST criteria	5 years